Phenelzine

Base Information

• Chemical Name: Phenelzine
• CAS No.: 51-71-8
• Molecular Formula: C8H12 N2
• Molecular Weight: 136.197
• Hs Code.: 2928000090
• European Community (EC) Number: 200-117-9
• UNII: O408N561GF
• DSSTox Substance ID: DTXSID2041094
• Nikkaji Number: J4.125D
• Wikipedia: Phenelzine
• Wikidata: Q1747559
• NCI Thesaurus Code: C61888
• RXCUI: 8123
• Pharos Ligand ID: J3GHUZ53VLF7
• Metabolomics Workbench ID: 43075
• ChEMBL ID: CHEMBL1089
• Mol file: 51-71-8.mol

Synonyms:2 Phenethylhydrazine;2-Phenethylhydrazine;beta Phenylethylhydrazine;beta-Phenylethylhydrazine;Fenelzin;Nardelzine;Nardil;Phenelzine;Phenelzine Sulfate;Phenethylhydrazine;Sulfate, Phenelzine

Chemical Property of Phenelzine

Chemical Property:

• Melting Point: 25°C
• Refractive Index: nD20 1.5494
• Boiling Point: 281.4 °C at 760 mmHg
• PKA: 8.01±0.70(Predicted)
• Flash Point: 143.7 °C
• PSA: 38.05000
• Density: 1.01 g/cm³
• LogP: 1.78360
• XLogP3: 1.2
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 2
• Rotatable Bond Count: 3
• Exact Mass: 136.100048391
• Heavy Atom Count: 10
• Complexity: 77.3

Purity/Quality:

98%,99%, ^*data from raw suppliers

2-Phenylethylhydrazine ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi
• Hazard Codes: Xi

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antidepressant Agents
• Canonical SMILES: C1=CC=C(C=C1)CCNN
• Recent ClinicalTrials: Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants
• Recent EU Clinical Trials: A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS
• Description: Monoamine oxidase inhibitors (MAOIs) were the first antidepressant drugs introduced during the 1950s. Associated with many side effects and, in particular, drug–drug and drug–food interactions, their use declined with the subsequent introduction of the tricyclic antidepressants and specific serotonin reuptake inhibitors as first-line treatments for depression.
• Uses: Phenelzine is a MAO inhibitor which is used for treating patients with depressive characteristics such as “atypical,” “nonendogenous,” or “neurotic” conditions in which a combination of anxiety, depression, or phobia are observed. Phenelzine is not a drug of first choice, and it is used in depressions that do not respond to other medicinal drugs. Antidepressant. MAOIs are used to treat atypical and refractory depression. They have also been used in the treatment of panic attacks, narcolepsy, and bulimia. Selective monoamine oxidase B (MAO-B) inhibitors such as selegiline are used to treat Parkinson’s disease.
• Therapeutic Function: Psychostimulant
• Drug interactions: Potentially hazardous interactions with other drugs Alcohol: some alcoholic and dealcoholised drinks contain tyramine which can cause hypertensive crisis. Alpha-blockers: avoid with indoramin; enhanced hypotensive effect. Analgesics: CNS excitation or depression with pethidine, other opioids and nefopam - avoid; increased risk of serotonergic effects and convulsions with tramadol - avoid. Antidepressants: enhancement of CNS effects and toxicity. Care with all antidepressants including drug free periods when changing therapies. Antiepileptics: antagonism of anticonvulsant effect; avoid carbamazepine with or within 2 weeks of MAOIs. Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol. Antipsychotics: effects enhanced by clozapine. Atomoxetine: avoid concomitant use and for 2 weeks after use. Bupropion: avoid with or for 2 weeks after MAOIs. Dapoxetine: risk of hypertensive crisis - avoid. Diuretics: avoid with indoramin. Dopaminergics: avoid with entacapone and tolcapone; hypertensive crisis with levodopa and rasagiline - avoid for at least 2 weeks after stopping MAOI; hypotension with selegiline. 5HT1 agonist: risk of CNS toxicity with sumatriptan, rizatriptan and zolmitriptan - avoid sumatriptan and rizatriptan for 2 weeks after MAOI. Methyldopa: avoid concomitant use. Opicapone: avoid concomitant use. Sympathomimetics: hypertensive crisis with sympathomimetics - avoid with methylphenidate. Tetrabenazine: risk of CNS excitation and hypertension avoid.

Technology Process of Phenelzine

There total 6 articles about Phenelzine which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

2-phenylethanol (60-12-8) → Phenelzine (51-71-8)

Guidance literature:

Multi-step reaction with 2 steps

1: PCl₅

2: ethanol; hydrazine hydrate

With ethanol; phosphorus pentachloride; hydrazine hydrate;

Reference yield:

2-phenylethyl chloride (622-24-2) → Phenelzine (51-71-8)

Guidance literature:

With hydrazine;

Reference yield:

→ Phenelzine (51-71-8)

Guidance literature:

With platinum; Hydrogenation;

DOI:10.1021/ja01520a048

upstream raw materials:

2-phenylethyl chloride

1-phenyl-2-bromoethane

2-phenylethanol

Downstream raw materials:

3-methyl-isoxazole-5-carboxylic acid N'-phenethyl-hydrazide

(3-Methoxy-phenyl)-phenyl-acetic acid N'-phenethyl-hydrazide

ethyl [3,5-dimethyl-1-(2-phenylethyl)-1H-pyrazol-4-yl]acetate

1-(2-phenylethyl)-6-thioxo-1,5,6,7-tetrahydro-4H-pyrazolo[3,4-d]pyrimidin-4-one

Refernces

• 1、 -. "Synthesis method of phenelzine". Paragraph 0007; 0008; 0009; 0010. . Retrieved 2018/08/04.